Ray Furey
Executive Vice President, General Counsel, and Corporate Secretary
Replay available
Rigel Pharmaceuticals, Inc. (RIGL) Q2 2025 Earnings Call
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) Q2 2025 earnings conference call, held 2025-08-05. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Raul Rodriguez
President and Chief Executive Officer
Dave Santos
Chief Commercial Officer
Lisa Royker
Chief Medical Officer
Dean Shorno
Chief Financial Officer
Joe Pantginas
Analyst, H.C. Wainwright
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Rigel Pharmaceuticals, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:05.197 Greetings and welcome to Rigel Pharmaceuticals financial conference call 00:00:05.197 -- 00:00:08.178 for the second quarter 2025. 00:00:08.781 -- 00:00:13.566 At this time, all participants are in a listen only mode. 00:00:13.566 -- 00:00:17.791 A brief question and answer session will follow the formal presentation. 00:00:17.791 -- 00:00:21.775 If anyone should require operator assistance during the conference, please press star 00:00:21.775 -- 00:00:27.605 zero on your telephone keypad. As a reminder, this conference is being recorded. 00:00:27.605 -- 00:00:32.753 It is now my pleasure to introduce our first speaker, Ray Furey, Rigel's 00:00:32.753 -- 00:00:37.339 Executive Vice President, General Counsel, and Corporate Secretary. 00:00:37.339 -- 00:00:40.701 Thank you, Mr. Furey. You may begin. 00:00:41.405 -- 00:00:46.233 Welcome to our second quarter of 2025 financial results and business update conference 00:00:46.233 -- 00:00:51.260 call. The financial press release for the second quarter of 2025 was issued a 00:00:51.260 -- 00:00:56.545 short while ago and can be viewed along with the slides for this presentation. 00:00:56.545 -- 00:01:01.972 in the news and events section of our investor relations site on Rizal.com. 00:01:01.972 -- 00:01:07.379 As a reminder, during today's call, we may make forward-looking statements regarding 00:01:07.379 -- 00:01:13.026 our financial outlook and our plans and timing for regulatory and product development. 00:01:13.026 -- 00:01:17.752 These statements are subject to risks and uncertainties that may cause actual results 00:01:17.752 -- 00:01:20.215 to differ from those forecasted. 00:01:20.215 -- 00:01:26.313 A description of these risks can be found in our most recent annual report on F...